SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sormani, M P
Right arrow Articles by Filippi, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sormani, M P
Right arrow Articles by Filippi, M
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Multiple Sclerosis
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis

M P Sormani

Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, 20132 Milan, Italy, Unit of Clinical Epidemiology, National Institute for Cancer Research, 16132 Genoa, Italy

P Bruzzi

Unit of Clinical Epidemiology, National Institute for Cancer Research, 16132 Genoa, Italy

G Comi

Department of Neurology, Scientific Institute and University Ospedale San Raffaele, 20132 Milan, Italy

M Filippi

Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, 20132 Milan, Italy, Department of Neurology, Scientific Institute and University Ospedale San Raffaele, 20132 Milan, Italy, filippi.massimo{at}hsr.it

We investigated the distribution of the magnetic resonance imaging (MRI)-measured response to glatiramer acetate (GA) treatment in multiple sclerosis (MS) using data from a clinical trial of relapsing=remitting (RR) MS. A fixed and a random effects model were used to quantify the between-patient heterogeneity in treatment response, expressed as new enhancing lesion percentage reduction. In 95% of the patients, lesion reduction due to treatment was estimated to range between -20% and -54%, indicating a rather homogeneous effect of GA on MRI-measured disease activity in RRMS.

Key Words: MRI lesions • multiple sclerosis • shape of GA effect

Multiple Sclerosis, Vol. 11, No. 4, 447-449 (2005)
DOI: 10.1191/1352458505ms1178oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
B. Benedetti, D.J. Rigotti, S. Liu, M. Filippi, R.I. Grossman, and O. Gonen
Reproducibility of the Whole-Brain N-Acetylaspartate Level across Institutions, MR Scanners, and Field Strengths
AJNR Am. J. Neuroradiol., January 1, 2007; 28(1): 72 - 75.
[Abstract] [Full Text] [PDF]


Advertisement